Facebook
X
LinkedIn
ForwardMedetomidine: An Emerging Adulterant Reshaping Toxicity and Withdrawal Management 4.15.26
Target Audience
Physicians
Learning Objectives
1. Describe the emergence of medetomidine as an illicit drug adulterant and its impact on overdose toxicity and withdrawal presentations.
2. Recognize the clinical features of medetomidine toxicity and differentiate medetomidine withdrawal from opioid, benzodiazepine, and other sedative withdrawal syndromes.
3. Apply evidence-informed strategies for early, aggressive management of medetomidine withdrawal, including the use of alpha-2 agonists and antiemetic therapies.
4. Identify system-level challenges posed by medetomidine—including diagnostic limitations, disposition uncertainty, and ICU resource burden—and outline approaches to multidisciplinary coordination.
Additional Information
Agenda:
12:00-12:05: Introduction
12:05-12:35: Didactic presentation of existing knowledge and evidence (Dr. Lynch)
12:35-12:45: Moderated discussion by select addiction providers (Led by Dr. Lynch)
12:45-1:00: Discussion with Q&A, Conclusion (Moderated by Dr. Lynch)
Disclaimer Statement
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Michale Lynch MD
Disclaimer Statement
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Accreditation and credit designation
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician (CME)
The University of Pittsburgh School designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professionals
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 1.00 Attendance